• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Phathom

Quote








anonymous said:
By Q3
Click to expand...

You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
 




anonymous said:
You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
Click to expand...

You think the stock is up based on the weekly rx report lol.
 




anonymous said:
You are all idiots. No cuts will happen until end of Q4 at the earliest. This doesn't mean the idiots with less than 10 scripts won't be shown the door SOON. Stock is up today based on the weekly Rx report. You are all stupid to think each movement has anything to do with anything. You primary reps are dumber than I thought!
Click to expand...

“the idiots with less than 10 scripts”

some of us don’t have the fortune of having speakers in their territory, had a later start than the people who’ve been here since Nov & are predominately filled with primary care providers. Wait until we’re actually goaled based on geographic potential, you’ll be in the mud soon enough.
 




The uptick has been slower than anticipated and BlinkRx has been underwhelming at best, but multiple physicians I have spoken with that put patients on Voquezna have heard phenomenal feedback from those patients. This drug is going to take off and if it gets approved for NERD it's going to skyrocket.

I've launched multiple blockbusters and the forecasts by analysts are almost always way to high for the first 9-12 months.
 




























anonymous said:
The uptick has been slower than anticipated and BlinkRx has been underwhelming at best, but multiple physicians I have spoken with that put patients on Voquezna have heard phenomenal feedback from those patients. This drug is going to take off and if it gets approved for NERD it's going to skyrocket.

I've launched multiple blockbusters and the forecasts by analysts are almost always way to high for the first 9-12 months.
Click to expand...

tell that to management
 
















anonymous said:
classic POS rep! Glad the herd will be culled soon and we’ll be looking for trends like this. Nice job!
Click to expand...

Seriously? Reps will ALWAYS work the plan. Management should take a serious look at their decision to change the rules mid way and make a 10 RX minimum. If they hired reps with any ability to think they should have expected this.
 
















Top Bottom
Back
Quote